Zymeworks Inc.

Contributing Author

Recent Articles by Zymeworks Inc.

Apr-09	Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth ZYME GlobeNewswire
Apr-01	Zymeworks Appoints Kristin Stafford as Chief Financial Officer ZYME GlobeNewswire
Mar-30	Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRa-Targeting Antibody-Drug Conjugate ZYME GlobeNewswire
Mar-24	Zymeworks Announces Participation in Upcoming Investor Conferences ZYME GlobeNewswire
Mar-18	Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting ZYME GlobeNewswire
Mar-17	Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting ZYME GlobeNewswire
Mar-02	Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing ZYME GlobeNewswire
Mar-02	Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results ZYME GlobeNewswire
Feb-12	Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 ZYME GlobeNewswire
Jan-27	Zymeworks Announces Participation in Upcoming Investor Conferences ZYME GlobeNewswire
Jan-12	Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy ZYME GlobeNewswire
Jan-11	Zymeworks Outlines Strategic Priorities and Outlook for 2026 ZYME GlobeNewswire
Jan-06	Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit ZYME -5.10% GlobeNewswire
Dec-02	Zymeworks Announces Participation in Upcoming Conferences ZYME GlobeNewswire
Nov-24	Zymeworks Announces Participation in Upcoming Investor Conferences ZYME GlobeNewswire
Nov-18	Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer ZYME GlobeNewswire
Nov-18	Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets ZYME GlobeNewswire
Nov-17	Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma ZYME +29.05% GlobeNewswire
Nov-06	Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results ZYME -8.04% ZYME GlobeNewswire
Oct-28	Zymeworks Announces Participation in Upcoming Investor Conferences ZYME GlobeNewswire
Oct-23	Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference ZYME GlobeNewswire
Oct-16	Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 ZYME GlobeNewswire
Oct-13	Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference ZYME GlobeNewswire
Oct-09	Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer ZYME GlobeNewswire
Sep-02	Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager ZYME -5.40% GlobeNewswire
Aug-19	Zymeworks Announces Participation in Upcoming Investor Conferences ZYME GlobeNewswire
Aug-11	Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry ZYME GlobeNewswire
Aug-07	Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results ZYME GlobeNewswire
Jul-28	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate ZYME GlobeNewswire
Jul-17	Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 ZYME +7.10% GlobeNewswire
May-30	Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer ZYME GlobeNewswire
May-22	Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences ZYME GlobeNewswire
May-21	Zymeworks Announces Participation in Upcoming Investor Conferences ZYME GlobeNewswire
May-19	Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference ZYME +5.16% ZYME GlobeNewswire
May-08	Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results ZYME GlobeNewswire

Zymeworks Inc.

Recent Articles by Zymeworks Inc.

Upgrade your Finviz experience